Feasibility of a Home Exercise Program to Manage Post-transplant Metabolic Syndrome
Feasibility of a Home-Based Exercise Program in Lung and Liver Transplant Recipients for Management of Post-Transplant Metabolic Syndrome: a Pilot Randomized Controlled Trial
1 other identifier
interventional
26
1 country
1
Brief Summary
Post-transplant metabolic syndrome (PTMS) affects about 50% liver transplant (OLT) and 25% lung transplant (LTx) recipients at 12-18 months post-transplant. PTMS (comprised of glucose intolerance, obesity, hypercholesterolemia and hypertension) has been associated with increased risk for cardiovascular morbidity and long-term survival. Exercise studies in the early post-transplant period have shown some benefits on PTMS risk factors with facility-based training, but it remains unclear if exercise can be sustained in the home environment with sufficient adherence or training intensity to impact PTMS beyond the early post-transplant period. Objectives: 1) To evaluate the feasibility of a three-month individualized, virtual home-based exercise training program in OLT and LTx recipients starting at 1 year post-transplant. 2) To assess estimates of intervention efficacy on elements of PTMS, insulin resistance, exercise self-efficacy, and health related quality of life (HRQL). Methods: 20 OLT and 20 LTx recipients with 2 or more PTMS risk factors at 12-18 months post-transplant will be randomized to a home-based exercise program versus usual care. The exercise group will undergo aerobic training 3 to 5 times per week with resistance training at least twice weekly over a 12-week period. Exercises will be demonstrated by a qualified exercise professional during the first visit with weekly phone and video calls to guide exercise progression, ease communication and promote exercise self-efficacy and adherence based on guiding behavioral principles. As secondary measures, PTMS, insulin resistance, body composition (optional), HRQL, and assessment of self-efficacy will be assessed at baseline and 12-weeks.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Aug 2021
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 17, 2021
CompletedFirst Posted
Study publicly available on registry
July 16, 2021
CompletedStudy Start
First participant enrolled
August 19, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 30, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
July 30, 2024
CompletedNovember 26, 2024
November 1, 2024
2.8 years
June 17, 2021
November 22, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (6)
Recruitment
We will measure recruitment-success percentage and will record reasons for non-participation.
When recruitment is complete (approximately 18 months after study initiation)
Adherence to Exercise Training
Adherence to the home-based exercise program (aerobic and resistance) will be measured through an exercise diary completed by participants and reviewed through weekly communication.
Over a 12 week period
Study Retention
Retention will be assessed by measuring attrition throughout the intervention period.
Over a 12 week period
Adverse Events During Exercise Training (Safety and Tolerability)
Adverse events with exercise training will be assessed throughout the study period.
Over a 12 week period
Participant Satisfaction with Exercise Training and Study Participation (Exercise Group)
Multiple choice and free form questionnaire assessing the participants' satisfaction with the home exercise program and study intervention.
Change over the study period assessed at weeks 2, 6, and 12
Participant Satisfaction with Study Participation (Control Group)
Multiple choice and free form questionnaire assessing participants' satisfaction with the study intervention.
12 weeks from baseline assessment
Secondary Outcomes (16)
Total Cholesterol
Change from baseline at 12 weeks
Triglycerides
Change from baseline at 12 weeks
High Density Lipoprotein
Change from baseline at 12 weeks
Low Density Lipoprotein
Change from baseline at 12 weeks
Fasting Blood Glucose Levels
Change from baseline at 12 weeks
- +11 more secondary outcomes
Other Outcomes (4)
Liver Fibrosis
Change from baseline at 12 weeks
Fat Free Mass Index
Change from baseline at 12 weeks
Body Fat Mass Index
Change from baseline at 12 weeks
- +1 more other outcomes
Study Arms (2)
Home Exercise Group
EXPERIMENTALThe home-based exercise group will be asked to exercise 3 to 5 times per week (≥ 150 minutes of aerobic exercises (i.e. walking, cycling, or treadmill) of at least moderate intensity) and to also complete resistance training (resistance bands or free weights) at least twice weekly over a 12-week period supervised by an exercise professional. The resistance training will be personalized, aiming for 6 to 10 exercises targeting the major muscle groups, progressing to 3 sets of 8 to 12 repetitions. Exercise prescriptions will be developed and monitored by an exercise professional with weekly follow-up meetings and supported with a web application (Physiotec) that allows customizable exercise prescriptions, tracking of exercise completion, and video tutorials. Participants will receive one counselling session on healthy eating and physical activity at the start of the study along with an exercise manual.
Control Group
NO INTERVENTIONParticipants will receive one counselling session on healthy eating and physical activity at the start of the study.
Interventions
The intervention group will be asked to complete aerobic exercises 3 to 5 times per week (≥ 150 minutes of at least moderate aerobic intensity) and resistance training at least twice a week over a 12-week period.
Eligibility Criteria
You may qualify if:
- Adult lung and liver transplant recipients 12 to 18 months post-transplant
- Presence of 2 or more metabolic risk factors (hypertension, hyperlipidemia, diabetes, obesity)
You may not qualify if:
- Active cardiovascular disease (recent heart attack, significant coronary artery disease on cardiac catheterization, heart failure, uncontrolled arrhythmias, chest pain, dizziness, or fainting in the last 3 months)
- Neuro-muscular disease or orthopedic limitations
- Physically active with ≥ 150 minutes/week of moderate-intensity aerobic physical activity
- Residing outside the province of Ontario
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University Health Network, Torontolead
- Canadian National Transplant Research Programcollaborator
- University of Torontocollaborator
Study Sites (1)
University Health Network - Toronto General Hospital
Toronto, Ontario, M5G 2C4, Canada
Related Publications (1)
Rozenberg D, Santa Mina D, Nourouzpour S, Camacho Perez E, Stewart BL, Wickerson L, Tsien C, Selzner N, Shore J, Aversa M, Woo M, Holdsworth S, Prevost K, Park J, Azhie A, Huszti E, McLeod E, Dales S, Bhat M. Feasibility of a Home-Based Exercise Program for Managing Posttransplant Metabolic Syndrome in Lung and Liver Transplant Recipients: Protocol for a Pilot Randomized Controlled Trial. JMIR Res Protoc. 2022 Mar 23;11(3):e35700. doi: 10.2196/35700.
PMID: 35319467DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Dmitry Rozenberg, MD PhD
University Health Network /University of Toronto
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 17, 2021
First Posted
July 16, 2021
Study Start
August 19, 2021
Primary Completion
May 30, 2024
Study Completion
July 30, 2024
Last Updated
November 26, 2024
Record last verified: 2024-11
Data Sharing
- IPD Sharing
- Will not share